{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-117728","form_type":"8-K","ticker":"NNVC","cik":"0001379006","company_name":"NANOVIRICIDES, INC.","filed_at":"2021-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.893310+00:00","generated_at":"2026-06-29T02:16:30.453957+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NanoViricides reports NV-CoV-2-R shows nearly 2x intact remdesivir in plasma vs standard in rat study","bullets":["Almost double intact remdesivir in plasma on day 1 of dosing with NV-CoV-2-R vs standard remdesivir.","After fifth dose (day 7), circulating remdesivir 75% greater in NV-CoV-2-R group.","NV-CoV-2-R combines nanoviricides platform attack on virus outside cells with remdesivir inside cells.","Company expects improved pan-coronavirus activity retaining effectiveness against emerging variants.","Draft data inadvertently published; final press release expected by September 28, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-117728","json":"https://secwatch.observer/filing/0001104659-21-117728.json","markdown":"https://secwatch.observer/filing/0001104659-21-117728.md","text":"https://secwatch.observer/filing/0001104659-21-117728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379006/000110465921117728/0001104659-21-117728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379006/000110465921117728/tm2128140d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T02:16:30.453957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}